Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label rigosertib study in RDEB-associated advanced squamous cell carcinoma
2016-003832-19Phase 2Active
- Sponsor
- Salzburger Landeskliniken
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in squamous cell carcinoma (SCC) and Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Salzburger Landeskliniken. Primary endpoint: Overall response rate. Started Aug 2017; status: active.
02
Drugs
rigosertib
03
Conditions
squamous cell carcinoma (SCC)Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on 2016-003832-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003832-19.